Search
Rogaratinib
go.drugbank.com/drugs/DB15078InvestigationalRogaratinib is under investigation in clinical trial NCT03762122 (Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC)).
Categories: Heterocyclic Compounds, 1-RingGefapixant
go.drugbank.com/drugs/DB15097ApprovedIt has been estimated that 5-10% of adults globally suffer from chronic cough, which is defined as a cough lasting longer than eight weeks. … [L48601] A subset of these patients remain symptomatic despite thorough investigation and treatment, termed refractory chronic cough (RCC) if they have a cough that does not respond to conventional treatment
Categories: MATE 1 Substrates, MATE 2 SubstratesRSV-604
go.drugbank.com/drugs/DB15197InvestigationalRSV-604 is under investigation in clinical trial NCT00416442 (Safety, Tolerability and Pharmacokinetic Study of Single and Multiple Intravenous Doses of RSV604 in Healthy Subjects.).
Categories: Heterocyclic Compounds, 2-RingAvutometinib
go.drugbank.com/drugs/DB15254ApprovedInvestigationalAvutometinib is a small molecule kinase inhibitor targeted against RAF/MEK1, key regulators of the RAS/RAF/MEK/ERK (MAPK) pathway. … [L53203,L53198] The MAPK pathway is implicated in variety of cancers, playing a key role in tumor cell proliferation, differentiation and survival.
Synonyms: N-(3-fluoro-4-((4-methyl-2-oxo-7-((pyrimidin-2-yl)oxy)-2H-1-benzopyran-3-yl)methyl)pyridin-2-yl)-N'-methylsulfuric diamide, Sulfamide, N-(3-fluoro-4-((4-methyl-2-oxo-7-(2-pyrimidinyloxy)-2H-1-benzopyran-3-yl)methyl)-2-pyridinyl)-N'-methyl-Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesAbivertinib
go.drugbank.com/drugs/DB15327Investigational[L17383] It has been investigated for use in the treatment of non-small cell lung cancer (NSCLC) and B-cell malignancies. … Abivertinib is a tyrosine kinase inhibitor targeted against mutant forms of both human epidermal growth factor receptor (EGFR) and Bruton's tyrosine kinase (BTK).
Categories: Heterocyclic Compounds, 1-RingBalcinrenone
go.drugbank.com/drugs/DB15418InvestigationalAZD-9977 is under investigation in clinical trial NCT03843060 (A Phase 1 Study to Assess the Pharmacokinetics of AZD9977 Administered Alone and in Combination With Itraconazole in Healthy Volunteers).
Categories: Heterocyclic Compounds, 1-RingBelzutifan
go.drugbank.com/drugs/DB15463ApprovedInvestigational[L35995] The HIF-2α protein was first identified in the 1990s by researchers at UT Southwestern Medical Center as a key player in the growth of certain cancers. … [L36105] Initially considered to be undruggable, a binding pocket was eventually discovered in the HIF-2α molecule which allowed for compounds to bind and inhibit these proteins.
Categories: MATE 2 Inhibitors, Cytochrome P-450 SubstratesPrednisolone acetate
go.drugbank.com/drugs/DB15566ApprovedInvestigationalVet approvedPrednisolone acetate is a [prednisolone] molecule bound to an acetate functional group by an ester bond.[L9449] Prednisolone acetate was granted FDA approval in 1955.[L9449]
Mixtures: PREFOX-T®, CONJUNTIN-S® LIQUIFILM® SUSPENSION OFTALMICA ESTERILCategories: P-glycoprotein substrates, Cytochrome P-450 SubstratesSotorasib
go.drugbank.com/drugs/DB15569ApprovedInvestigational[A187547] Sotorasib was granted FDA approval on May 28, 2021,[L34288] followed by the European Commission's approval on January 6, 2022.[L56070] … [A187550] Mutant KRAS discovered in 1982 but was not considered a druggable target until the mid-2010s.[A235168] It is the first experimental KRAS inhibitor.
Synonyms: 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-(1M)-1-[4-methyl-2-(propan-2-yl)pyridin-3-yl]-4-[(2S)-2- methyl-4-(prop-2-enoyl)piperazin-1-yl]pyrido[2,3-d]pyrimidin-2(1H)-one, Kras G12C inhibitor 9Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesUlotaront
go.drugbank.com/drugs/DB15665InvestigationalUnlike other drugs used for this condition, SEP-363856 does not bind to the dopamine D2 receptors, but exerts actions on the trace amine–associated receptor 1 (TAAR1) and 5-hydroxytryptamine type 1A (5 … SEP-363856 is a novel psychotropic drug being investigated for the treatment of schizophrenia.
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 Substrates